Notice of Proposed Sale · 144

Pacira BioSciences, Inc.

PCRXNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 17, 2026Accepted Aug 17, 2026, 11:54 AM EDTFiling CIK 1875723Accession 0001959173-26-006073

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: Pacira BioSciences, Inc.
Issuer CIK: 0001396814
SEC file number: 001-35060
Phone: 650-242-8052
Person for whose account securities are to be sold: SLONIN JONATHAN
Relationships to issuer: Officer
Street: 2000 SIERRA POINT PARKWAY
Street (continued): SUITE 900
City: BRISBANE
State / country code: CA
Postal code: 94005

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	3,040	70,619.20	39,861,886	08/17/2026	NASDAQ	Fidelity Brokerage Services LLC

Broker / market maker — proposed row 1, entry 1

Name: Fidelity Brokerage Services LLC
Street: 900 Salem Street
City: Smithfield
State / country code: RI
Postal code: 02917

Acquisition of securities to be sold

Acquisition of securities to be sold · 2 reported rows
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	06/30/2022	ESPP Purchase	Issuer	214	N	06/30/2022	Cash
Common	07/01/2022	Restricted Stock Vesting	Issuer	2,826	N	07/01/2022	Compensation

Prior-sale reporting

Nothing to report for the preceding three months: Y

Notice signature

Notice date: 08/17/2026
Signed: /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jonathan Slonin
Plan adoption dates: 08/12/2025

Company context

Pacira BioSciences, Inc. (Nasdaq: PCRX) delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has two commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic for post-surgical pain management and ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain. Pacira is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies. Its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www. Pacira.com.

Current securities

PCRXNASDAQ · EQUITY · Current

Get the free weekly BCS email.